{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T15:42:53Z","timestamp":1785598973111,"version":"3.56.0"},"reference-count":41,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Canadian Institutes of Health Research (CIHR)","award":["CPG-151958"],"award-info":[{"award-number":["CPG-151958"]}]},{"name":"the Canadian Institutes of Health Research (CIHR)","award":["CHRPJ-508335-17"],"award-info":[{"award-number":["CHRPJ-508335-17"]}]},{"name":"the Canadian Institutes of Health Research (CIHR)","award":["CRC-240394"],"award-info":[{"award-number":["CRC-240394"]}]},{"name":"the Natural Sciences and Engineering Research Council (NSERC)","award":["CPG-151958"],"award-info":[{"award-number":["CPG-151958"]}]},{"name":"the Natural Sciences and Engineering Research Council (NSERC)","award":["CHRPJ-508335-17"],"award-info":[{"award-number":["CHRPJ-508335-17"]}]},{"name":"the Natural Sciences and Engineering Research Council (NSERC)","award":["CRC-240394"],"award-info":[{"award-number":["CRC-240394"]}]},{"name":"Canada Research Chair","award":["CPG-151958"],"award-info":[{"award-number":["CPG-151958"]}]},{"name":"Canada Research Chair","award":["CHRPJ-508335-17"],"award-info":[{"award-number":["CHRPJ-508335-17"]}]},{"name":"Canada Research Chair","award":["CRC-240394"],"award-info":[{"award-number":["CRC-240394"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>New influenza strains are constantly emerging, causing seasonal epidemics and raising concerns to the risk of a new global pandemic. Since vaccination is an effective method to prevent the spread of the disease and reduce its severity, the development of robust bioprocesses for producing pandemic influenza vaccines is exceptionally important. Herein, a membrane chromatography-based downstream processing platform with a demonstrated industrial application potential was established. Cell culture-derived influenza virus H1N1\/A\/PR\/8\/34 was harvested from benchtop bioreactor cultures. For the clarification of the cell culture broth, a depth filtration was selected as an alternative to centrifugation. After inactivation, an anion exchange chromatography membrane was used for viral capture and further processing. Additionally, two pandemic influenza virus strains, the H7N9 subtype of the A\/Anhui\/1\/2013 and H3N2\/A\/Hong Kong\/8\/64, were successfully processed through similar downstream process steps establishing optimized process parameters. Overall, 41.3\u201362.5% viral recovery was achieved, with the removal of 86.3\u201396.5% host cell DNA and 95.5\u201399.7% of proteins. The proposed membrane chromatography purification is a scalable and generic method for the processing of different influenza strains and is a promising alternative to the current industrial purification of influenza vaccines based on ultracentrifugation methodologies.<\/jats:p>","DOI":"10.3390\/vaccines10081310","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T03:40:32Z","timestamp":1660621232000},"page":"1310","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Membrane Chromatography-Based Downstream Processing for Cell-Culture Produced Influenza Vaccines"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6780-7293","authenticated-orcid":false,"given":"Zeyu","family":"Yang","sequence":"first","affiliation":[{"name":"Viral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montreal, QC H3A 0G4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingge","family":"Xu","sequence":"additional","affiliation":[{"name":"Viral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montreal, QC H3A 0G4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina A. T.","family":"Silva","sequence":"additional","affiliation":[{"name":"Viral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montreal, QC H3A 0G4, Canada"},{"name":"Department of Chemical Engineering, Polytechnique Montreal, Montreal, QC H3T 1J4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1295-8323","authenticated-orcid":false,"given":"Omar","family":"Farnos","sequence":"additional","affiliation":[{"name":"Viral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montreal, QC H3A 0G4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Venereo-Sanchez","sequence":"additional","affiliation":[{"name":"Viral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montreal, QC H3A 0G4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Toussaint","sequence":"additional","affiliation":[{"name":"Viral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montreal, QC H3A 0G4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shantoshini","family":"Dash","sequence":"additional","affiliation":[{"name":"Viral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montreal, QC H3A 0G4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7920-5505","authenticated-orcid":false,"given":"Irene","family":"Gonz\u00e1lez-Dom\u00ednguez","sequence":"additional","affiliation":[{"name":"Viral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montreal, QC H3A 0G4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Bernier","sequence":"additional","affiliation":[{"name":"Viral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montreal, QC H3A 0G4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Henry","sequence":"additional","affiliation":[{"name":"Department of Chemical Engineering, Polytechnique Montreal, Montreal, QC H3T 1J4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9110-8815","authenticated-orcid":false,"given":"Amine","family":"Kamen","sequence":"additional","affiliation":[{"name":"Viral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montreal, QC H3A 0G4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/irv.12362","article-title":"Improving the representativeness of influenza viruses shared within the WHO Global Influenza Surveillance and Response System","volume":"10","author":"Pereyaslov","year":"2016","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e2243","DOI":"10.1002\/rmv.2243","article-title":"Influenza vaccines: Past, present, and future","volume":"32","author":"Kim","year":"2022","journal-title":"Rev. Med. Virol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Manceur, A.P., Zou, W., Marcil, A., Paquet, E., Gadoury, C., Jaentschke, B., Li, X., Petiot, E., Durocher, Y., and Baardsnes, J. (2017). Generation of monoclonal pan-hemagglutinin antibodies for the quantification of multiple strains of influenza. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0180314"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Sharabi, S., Drori, Y., Micheli, M., Friedman, N., Orzitzer, S., Bassal, R., Glatman-Freedman, A., Shohat, T., Mendelson, E., and Hindiyeh, M. (2016). Epidemiological and Virological Characterization of Influenza B Virus Infections. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0161195"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Tong, S., Zhu, X., Li, Y., Shi, M., Zhang, J., Bourgeois, M., Yang, H., Chen, X., Recuenco, S., and Gomez, J. (2013). New World Bats Harbor Diverse Influenza A Viruses. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003657"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/nm1201-1286","article-title":"Death by influenza virus protein","volume":"7","author":"Lamb","year":"2001","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/emboj\/20.3.362","article-title":"Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein","volume":"20","author":"Yuan","year":"2001","journal-title":"Embo J."},{"key":"ref_8","unstructured":"Couch, R.B., Keitel, W.A., Cate, T.R., Quarles, J.A., Taber, L.A., and Glezen, W.P. (1996, January 4\u20139). Prevention of influenza virus infections by current inactivated influenza virus vaccines. Proceedings of the 3rd International Conference on Options for the Control of Influenza, Cairns, Australia."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0140-6736(99)11433-8","article-title":"Influenza virus neuraminidase inhibitors","volume":"355","author":"Gubareva","year":"2000","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"104545","DOI":"10.1016\/j.antiviral.2019.104545","article-title":"Antivirals targeting the polymerase complex of influenza viruses","volume":"169","author":"Mifsud","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","article-title":"Influenza","volume":"4","author":"Krammer","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(04)16934-1","article-title":"Resistant influenza A viruses in children treated with oseltamivir: Descriptive study","volume":"364","author":"Kiso","year":"2004","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3389\/fcimb.2019.00344","article-title":"The Quest for a Truly Universal Influenza Vaccine","volume":"9","author":"Jang","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/14760584.2019.1639503","article-title":"Challenges in the development of egg-independent vaccines for influenza","volume":"18","author":"Trombetta","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1002\/cjce.24197","article-title":"Recent advances and current challenges in process intensification of cell culture-based influenza virus vaccine manufacturing","volume":"99","author":"Silva","year":"2021","journal-title":"Can. J. Chem. Eng."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"104886","DOI":"10.1016\/j.antiviral.2020.104886","article-title":"Functional neuraminidase inhibitor resistance motifs in avian influenza A(H5Nx) viruses","volume":"182","author":"Bialy","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_17","first-page":"2515135518821625","article-title":"A review of H5Nx avian influenza viruses","volume":"7","author":"Ross","year":"2019","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1016\/j.vaccine.2022.02.040","article-title":"WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants\u2014Key considerations for global use","volume":"40","author":"Sparrow","year":"2022","journal-title":"Vaccine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1080\/21645515.2015.1016666","article-title":"Cell culture-based influenza vaccines: A necessary and indispensable investment for the future","volume":"11","author":"Hegde","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7117","DOI":"10.1016\/j.vaccine.2019.03.024","article-title":"The stability and immunogenicity of inactivated MDCK cell-derived influenza H7N9 viruses","volume":"37","author":"Tzeng","year":"2019","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Chia, M.Y., Hu, A.Y., Tseng, Y.F., Weng, T.C., Lai, C.C., Lin, J.Y., Chen, P.L., Wang, Y.F., Chao, S.R., and Chang, J.Y. (2015). Evaluation of MDCK cell-derived influenza H7N9 vaccine candidates in ferrets. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0120793"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Chen, P.L., Tzeng, T.T., Hu, A.Y., Wang, L.H., and Lee, M.S. (2020). Development and Evaluation of Vero Cell-Derived Master Donor Viruses for Influenza Pandemic Preparedness. Vaccines, 8.","DOI":"10.3390\/vaccines8040626"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/bit.25545","article-title":"Improved virus purification processes for vaccines and gene therapy","volume":"112","author":"Nestola","year":"2015","journal-title":"Biotechnol. Bioeng."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1016\/j.vaccine.2016.04.089","article-title":"Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: An effective influenza vaccine candidate","volume":"34","author":"Gilbert","year":"2016","journal-title":"Vaccine"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Thompson, C.M., Petiot, E., Mullick, A., Aucoin, M.G., Henry, O., and Kamen, A.A. (2015). Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems. BMC Biotechnol., 15.","DOI":"10.1186\/s12896-015-0152-x"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1016\/j.vaccine.2017.03.016","article-title":"A fast and efficient purification platform for cell-based influenza viruses by flow-through chromatography","volume":"36","author":"Tseng","year":"2018","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1080\/10826068.2014.985834","article-title":"Continuous Processing for Production of Biopharmaceuticals","volume":"45","author":"Rathore","year":"2015","journal-title":"Prep. Biochem. Biotechnol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Dom\u00ednguez, I., Lorenzo, E., Bernier, A., Cervera, L., G\u00f2dia, F., and Kamen, A. (2021). A Four-Step Purification Process for Gag VLPs: From Culture Supernatant to High-Purity Lyophilized Particles. Vaccines, 9.","DOI":"10.3390\/vaccines9101154"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.seppur.2019.02.040","article-title":"Efficient filtration strategies for the clarification of influenza virus-like particles derived from insect cells","volume":"218","author":"Carvalho","year":"2019","journal-title":"Sep. Purif. Technol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jviromet.2012.03.031","article-title":"Purification of a recombinant baculovirus of Autographa californica M nucleopolyhedrovirus by ion exchange membrane chromatography","volume":"183","author":"Grein","year":"2012","journal-title":"J. Virol. Methods"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Kutner, R.H., Puthli, S., Marino, M.P., and Reiser, J. (2009). Simplified production and concentration of HIV-1-based lentiviral vectors using HYPERFlask vessels and anion exchange membrane chromatography. BMC Biotechnol., 9.","DOI":"10.1186\/1472-6750-9-10"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jviromet.2004.07.001","article-title":"Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock","volume":"121","author":"Davidoff","year":"2004","journal-title":"J. Virol. Methods"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/jmv.24771","article-title":"A novel preservative-free seasonal influenza vaccine safety and immune response study in the frame of preclinical research","volume":"89","author":"Sarsenbayeva","year":"2017","journal-title":"J. Med. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.5731\/pdajpst.2013.00910","article-title":"Establishing acceptable limits of residual DNA","volume":"67","author":"Yang","year":"2013","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.vaccine.2008.11.113","article-title":"HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines","volume":"27","author":"Kapteyn","year":"2009","journal-title":"Vaccine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1586\/erv.11.111","article-title":"Downstream processing of cell culture-derived virus particles","volume":"10","author":"Wolf","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.memsci.2007.04.048","article-title":"Direct capture of influenza A virus from cell culture supernatant with Sartobind anion-exchange membrane adsorbers","volume":"299","author":"Kalbfuss","year":"2007","journal-title":"J. Membr. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1128\/jvi.1.6.1207-1216.1967","article-title":"Purification of Large Quantities of Influenza Virus by Density Gradient Centrifugation","volume":"1","author":"Reimer","year":"1967","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10517-017-3964-y","article-title":"Comparison of Different Methods of Purification and Concentration in Production of Influenza Vaccine","volume":"164","author":"Asanzhanova","year":"2017","journal-title":"Bull. Exp. Biol. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jviromet.2014.06.019","article-title":"A flow-through chromatography process for influenza A and B virus purification","volume":"207","author":"Weigel","year":"2014","journal-title":"J. Virol. Methods"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/ceat.200800118","article-title":"Downstream Processing: From Egg to Cell Culture-Derived Influenza Virus Particles","volume":"6","author":"Wolff","year":"2008","journal-title":"Chem. Eng. Technol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/8\/1310\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:08:22Z","timestamp":1760141302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/8\/1310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,13]]},"references-count":41,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["vaccines10081310"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10081310","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,13]]}}}